Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | SCN4A | P35499 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | JMJD6 | Q6NYC1 | 3/20 | 0.33 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.33 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.30 |
| ▸ | PIP5K1C | O60331 | 1/20 | 0.30 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.30 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.30 |
| ▸ | PI4KA | P42356 | 1/20 | 0.30 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.30 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15541217 | 0.75 | BRD4 (0.43) | KDM4E | |
| SCHEMBL1848925 | 0.74 | BRD4 (0.40) | KDM4E | |
| SCHEMBL11071987 | 0.73 | ALDH1A1 (0.41) | KMT2AKDM4E | |
| SCHEMBL1970354 | 0.72 | KMT2A (0.46) | KMT2AKEAP1KDM4ESCN4ACYP19A1 | |
| SCHEMBL18157906 | 0.71 | KMT2A (0.64) | KMT2AKEAP1KDM4ESCN4ACYP19A1 | |
| SCHEMBL1672983 | 0.70 | PPARA (0.35) | — | |
| SCHEMBL18228301 | 0.70 | KMT2A (0.44) | KMT2AKEAP1KDM4ESCN4ACYP19A1 | |
| SCHEMBL2072830 | 0.69 | DRD4 (0.38) | KDM4E | |
| SCHEMBL1155310 | 0.69 | KMT2A (1.00) | KMT2AKEAP1KDM4ESCN4ACYP19A1 | |
| SCHEMBL115447 | 0.68 | CYP3A4 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365557-A1 | IMIDAZOPYRIDINYL COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | 1ST Biotherapeutics, Inc. (KR) | 2023-11-16 | — | — | US | claimed |
| US-11802126-B2 | Imidazopyridinyl compounds and use thereof for treatment of neurodegenerative disorders | 1ST Biotherapeutics, Inc. (KR) | 2023-10-31 | — | — | US | claimed |
| EP-3692023-B1 | BENZOTHIAZOL COMPOUNDS AND METHODS USING THE SAME FOR TREATING NEURODEGENERATIVE DISORDERS | 1ST BIOTHERAPEUTICS INC (KR) | 2023-05-17 | — | — | EP | claimed |
| EP-3927706-A1 | IMIDAZOPYRIDINYL COMPOUNDS AND USE THEREOF FOR TREATMENT OF PROLIFERATIVE DISORDERS | 1st Biotherapeutics, Inc. (KR) | 2021-12-29 | — | — | EP | claimed |
| EP-3927705-A1 | IMIDAZOPYRIDINYL COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | 1st Biotherapeutics, Inc. (KR) | 2021-12-29 | — | — | EP | claimed |
| US-20210347774-A1 | IMIDAZOPYRIDINYL COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | 1ST Biotherapeutics, Inc. | 2021-11-11 | — | — | US | claimed |
| WO-2021183702-A1 | GPX4 INHIBITORS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE FOR TREATING GPX4-MEDIATED DISEASES | EUBULUS BIOTHERAPEUTICS INC. (CN) | 2021-09-16 | — | — | WO | claimed |
| US-10968188-B2 | Benzothiazol compounds and methods using the same for treating neurodegenerative disorders | 1ST Biotherapeutics, Inc. (KR) | 2021-04-06 | — | — | US | claimed |
| US-20200270222-A1 | BENZOTHIAZOL COMPOUNDS AND METHODS USING THE SAME FOR TREATING NEURODEGENERATIVE DISORDERS | 1ST Biotherapeutics, Inc. | 2020-08-27 | — | — | US | claimed |
| US-20200270246-A1 | IMIDAZOPYRIDINYL COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | 1ST Biotherapeutics, Inc. | 2020-08-27 | — | — | US | claimed |
| EP-3692023-A1 | BENZOTHIAZOL COMPOUNDS AND METHODS USING THE SAME FOR TREATING NEURODEGENERATIVE DISORDERS | 1st Biotherapeutics, Inc. (KR) | 2020-08-12 | — | — | EP | claimed |
| US-10669246-B2 | Benzothiazol compounds and methods using the same for treating neurodegenerative disorders | 1ST Biotherapeutics, Inc. (KR) | 2020-06-02 | — | — | US | claimed |
| WO-2019070093-A1 | BENZOTHIAZOL COMPOUNDS AND METHODS USING THE SAME FOR TREATING NEURODEGENERATIVE DISORDERS | 1ST Biotherapeutics, Inc. (KR) | 2019-04-11 | — | — | WO | claimed |
| US-20190100500-A1 | BENZOTHIAZOL COMPOUNDS AND METHODS USING THE SAME FOR TREATING NEURODEGENERATIVE DISORDERS | 1ST Biotherapeutics, Inc. | 2019-04-04 | — | — | US | claimed |
| US-20150299163-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF PARASITIC DISEASES | IRBM - SCIENCE PARK S.P.A. (IT) | 2015-10-22 | — | — | US | claimed |
| EP-1797096-B1 | PYRAZOLOPYRIMIDINES AS INHIBITORS OF PROTEIN KINASE B (AKT) | BAYER SCHERING PHARMA AG (DE) | 2011-07-27 | — | — | EP | claimed |
| WO-2007135527-A2 | BENZIMIDAZOLYL COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2007-11-29 | — | — | WO | claimed |
| WO-2007135529-A2 | AZABENZIMIDAZOLYL COMPOUNDS AS MGLUR2 POTENTIATORS | PFIZER PRODUCTS INC. (US) | 2007-11-29 | — | — | WO | claimed |
| EP-1797096-A2 | NOVEL PYRAZOLOPYRIMIDINES | Altana Pharma AG (DE) | 2007-06-20 | — | — | EP | claimed |
| WO-2006027346-A2 | NOVEL PYRAZOLOPYRIMIDINES | ALTANA PHARMA AG (DE) | 2006-03-16 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365557-A1 | IMIDAZOPYRIDINYL COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | SMN1; SMN2, SNCA, HTT | KMT2A 2106/4885KEAP1 136/4885KDM4E 3156/4885 |
| US-20150299163-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF PARASITIC DISEASES | HDAC3, HDAC5, HDAC1 | KMT2A 71/4885KEAP1 451/4885KDM4E 336/4885 |
| US-20190100500-A1 | BENZOTHIAZOL COMPOUNDS AND METHODS USING THE SAME FOR TREATING NEURODEGENERATIVE DISORDERS | ABL2, ABL1, MAPT | KMT2A 1087/4885KEAP1 319/4885KDM4E 2026/4885 |
| US-11802126-B2 | Imidazopyridinyl compounds and use thereof for treatment of neurodegenerative disorders | SMN1; SMN2, SNCA, HTT | KMT2A 2106/4885KEAP1 136/4885KDM4E 3156/4885 |
| US-10669246-B2 | Benzothiazol compounds and methods using the same for treating neurodegenerative disorders | ABL2, ABL1, MAPT | KMT2A 1087/4885KEAP1 319/4885KDM4E 2026/4885 |
| US-10968188-B2 | Benzothiazol compounds and methods using the same for treating neurodegenerative disorders | ABL2, ABL1, MAPT | KMT2A 1087/4885KEAP1 319/4885KDM4E 2026/4885 |
| US-20200270246-A1 | IMIDAZOPYRIDINYL COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | SMN1; SMN2, SNCA, HTT | KMT2A 2106/4885KEAP1 136/4885KDM4E 3156/4885 |
| US-20210347774-A1 | IMIDAZOPYRIDINYL COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | SMN1; SMN2, SNCA, HTT | KMT2A 2106/4885KEAP1 136/4885KDM4E 3156/4885 |
| US-20200270222-A1 | BENZOTHIAZOL COMPOUNDS AND METHODS USING THE SAME FOR TREATING NEURODEGENERATIVE DISORDERS | ABL2, ABL1, MAPT | KMT2A 1087/4885KEAP1 319/4885KDM4E 2026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.